跳至主要内容
临床试验/NCT02230397
NCT02230397已完成3 期

Efficacy and Tolerance Evaluation of a Topical "Revitalizing" Face Day Cream: Comparison Within Subjects Versus Placebo

Derming SRL2 个研究点 分布在 1 个国家目标入组 33 人开始时间: 2013年10月最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
发起方
Derming SRL
入组人数
33
试验地点
2
主要终点
Profilometry: change from baseline (T4 and T8 vs. T0)

研究概览

简要总结

Aim of the study was to evaluate clinically and by non-invasive instrumental evaluations the "revitalizing" activity of a face cream applied twice a day, morning and evening, for an uninterrupted period of 8 weeks, by healthy female volunteers aged 45-55 years with face ritidosis and women aged 55-65 years not habitual user of antiage-creams.

The study foresaw the comparison within subjects of the study product versus placebo (half face method).

It was also aim of this study to evaluate products efficacy and cosmetic acceptability by the volunteers and tolerance both by investigator and volunteers.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Single Group
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
45 Years 至 65 Years(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • female healthy subjects
  • age 45-55 years
  • women aged 55-65 years who are not habitual user of antiage-creams
  • presence of moderate face ritidosis
  • agreeing to present at each study visit without make-up
  • accepting to not change their habits regarding food, physical activity, face cleansing and make- up use
  • accepting not to expose their face to strong UV irradiation (UV session, or sun bathes) during the entire duration of the study
  • accepting to sign the Informed consent form

排除标准

  • pregnancy
  • lactation
  • change in the normal habits regarding foods, physical activity, face cleansing and make-up use during the month preceding the test
  • sensitivity to the test products or theirs ingredients
  • subjects whose insufficient adhesion to the study protocol is foreseeable
  • participation in a similar study actually or during the previous 3 months
  • change in the normal life habits during the month preceding the inclusion
  • dermatological disease (dermatitis; presence of cutaneous disease on the tested area, as lesions, scars, malformations; recurrent facial/labial herpes)
  • clinical and significant skin condition on the test area (e.g. active eczema, dermatitis, psoriasis etc.)
  • endocrine disease
  • hepatic disorder
  • renal disorder
  • cardiac disorder
  • pulmonary disease
  • neurological or psychological disease
  • inflammatory/immunosuppressive disease
  • drug allergy
  • drugs/cutaneous medical or surgical procedures at level of the tested area during the previous 3 months
  • anti-inflammatory drugs, anti-histaminic, topic and systemic corticosteroids, narcotic, antidepressant, immunosuppressive drugs (with except of contraceptive or hormonal treatment starting from at least 1 year);
  • assumption of drugs able to influence the test results in the investigator opinion

结局指标

主要结局

Profilometry: change from baseline (T4 and T8 vs. T0)

时间窗: T0 (basal conditions), T4 and T8 (after 4 and 8 week-treatment)

A picture of crow's feet area was taken thanks to Primos compact portable device (GFMesstechnik); a software able to elaborate 3D representations of skin wrinkles as well as to measure skin principal profilometric parameters in vivo or on skin replicas, according to the law DIN EN ISO 4228; moreover the software compares directly the different images obtained at the times foresee by the protocol (T0, T4 and T8).The portable probe assures a constant distance from the skin as well as a fixed illumination angle of incidence; in this way is possible to acquire standardized and reproducible images.

次要结局

  • Optical colorimetry: change from baseline (T4 and T8 vs. T0)(T0 (basal condition), T4 and T8 (after 4 and 8 week-treatment))
  • Skin electrical capacitance: change from baseline (T4 and T8 vs. T0)(T0 (basal condition), T4 and T8 (after 4 and 8 week-treatment))
  • Photographic documentation:(T0 (basal condition), T4 and T8 (after 4 and 8 week-treatment))
  • Clinical evaluations: change from baseline (T4 and T8 vs. T0)(T0 (basal conditions), T4 and T8 (after 4 and 8 week-treatment))
  • Skin plastoelasticity: change from baseline (T4 and T8 vs. T0)(T0 (basal condition), T4 and T8 (after 4 and 8 week-treatment))
  • Spectophotometry: change from baseline (T4 and T8 vs. T0)(T0 (basal condition), T4 and T8 (after 4 and 8 week-treatment))
  • Tape stripping:(T0 (basal conditions), T4 and T8 (after 4 and 8 week-treatment))

研究者

发起方
Derming SRL
申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验